Alessandra Ferrajoli, MD
Enriched profileProfessor and Deputy Chair, Department of Leukemia; Associate Medical Director, Leukemia Center · The University of Texas MD Anderson Cancer Center
Alessandra Ferrajoli is Professor and Deputy Chair, Department of Leukemia; Associate Medical Director, Leukemia Center at The University of Texas MD Anderson Cancer Center. OpenAlex indexes 934 publications with 29,063 citations (h-index 93); ClinicalTrials.gov lists 19 registered studies with this person as an investigator.
Data verified 25 Aug 2026
Overview
Updated 27 Aug 2026
Alessandra Ferrajoli, M.D., is Professor and Deputy Chair, Department of Leukemia at The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, TX. The public record shows 934 publications with 29,063 citations (h-index 93), centered on Chronic Lymphocytic Leukemia Research, Lymphoma Diagnosis and Treatment, Chronic Myeloid Leukemia Treatments. It also documents an investigator role on 19 registered clinical trials, industry payments reported by 19 companies.
- Most recent indexed publication: 2026 · Cancers
- Top research focus: Chronic Lymphocytic Leukemia Research
- 19 registered trials on ClinicalTrials.gov
- Open Payments reporting from 19 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 12 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 385.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 19 registered studies on ClinicalTrials.gov. The most recent:
- HEALTH4CLL2: A Randomized Waitlist Control Trial of Behavioral Interventions in Patients With Chronic Lymphocytic Leukemia
Sponsor: M.D. Anderson Cancer Center
Industry payments
Updated 27 Aug 2026
19 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- BeOne Medicines USA, Inc.Program year202510 payments$10,073openpaymentsdata.cms.gov ↗
- AstraZeneca Pharmaceuticals LPProgram year20253 payments
- BeiGene USA, Inc.Program year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
73.3%BCL-2 Inhibitor55.4%Venclexta100%Part D≥12 patientsKinase inhibitor17.8%Calquence100%Part D<11 patientsAnti-infectives
13.9%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor13.9%Valacyclovir100%Part D<11 patientsMusculoskeletal
12.9%Xanthine oxidase inhibitor12.9%Allopurinol100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 27 Aug 2026
177 congress contributions (2004–2026) across AACR, ASCO, ASH per OpenAlex. The most recent:
- Long-term outcomes with addition of inotuzumab ozogamicin to HCVAD and sequential blinatumomab in adults with newly diagnosed B-ALL.
ASCO Annual Meeting
ASCO2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Ibrutinib with Venetoclax in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: A Phase II Study.
Blood cancer discovery
Clinical Trial2026 - Pharmacological profiling in CLL patients during pirtobrutinib therapy and disease progression.
Blood cancer journal
Letter2025
Most-cited works
by citation count (OpenAlex)- 01
- 02
- 03Ibrutinib and Venetoclax for First-Line Treatment of CLLArticle510 citations2019
- 04Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic LeukemiaArticle483 citations2022
- 05
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- ResearchGate
researchgate.net/scientific-contributions/Alessandra-Ferrajoli-39517094
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗ - Doximity
doximity.com/pub/alessandra-ferrajoli-md
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- LinkedIn
linkedin.com/posts/issnaf_alessandra-ferrajoli-md-joins-the-issnaf-activity-7194494539577896960-w0-C
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗ - Other
issnaf.org/membersinaction/alessandra-ferrajoli/ferrajoli-alessandra
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →issnaf.org ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →issnaf.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- Caring MD Award2006verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cllglobal.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vjhemonc.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Hagop Kantarjian, MD
The University of Texas MD Anderson Cancer Center
Gabriel Hortobagyi, MD
The University of Texas MD Anderson Cancer Center
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
Funda Meric-Bernstam, MD
The University of Texas MD Anderson Cancer Center